Cara Therapeutics (CARA - Free Report) reported $4.87 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 55%. EPS of -$0.52 for the same period compares to -$0.43 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $8.8 million, representing a surprise of -44.72%. The company delivered an EPS surprise of +1.89%, with the consensus EPS estimate being -$0.53.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Cara performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Collaborative revenue: $2.47 million versus $6.46 million estimated by four analysts on average.
- Revenue- Commercial supply revenue: $1.25 million compared to the $1.88 million average estimate based on three analysts. The reported number represents a change of -62.9% year over year.
- Revenue- Royalty revenue: $0.17 million compared to the $0.74 million average estimate based on three analysts.
View all Key Company Metrics for Cara here>>>Shares of Cara have returned -26.1% over the past month versus the Zacks S&P 500 composite's +1.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Cara Therapeutics (CARA - Free Report) reported $4.87 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 55%. EPS of -$0.52 for the same period compares to -$0.43 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $8.8 million, representing a surprise of -44.72%. The company delivered an EPS surprise of +1.89%, with the consensus EPS estimate being -$0.53.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Cara performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Collaborative revenue: $2.47 million versus $6.46 million estimated by four analysts on average.
- Revenue- Commercial supply revenue: $1.25 million compared to the $1.88 million average estimate based on three analysts. The reported number represents a change of -62.9% year over year.
- Revenue- Royalty revenue: $0.17 million compared to the $0.74 million average estimate based on three analysts.
View all Key Company Metrics for Cara here>>>Shares of Cara have returned -26.1% over the past month versus the Zacks S&P 500 composite's +1.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Get the latest research report on CARA - FREE